Identification of Metastasis Associated Antigen 1 (MTA1) by Serological Screening of Prostate Cancer cDNA Libraries
Geng Li*, 1, Deepak P Assudani#, 1, Aija Line2, Fuming Cao1, Amanda Miles1, Robert C Rees1, Stephanie E.B McArdle*, 1
Identifiers and Pagination:Year: 2008
First Page: 100
Last Page: 107
Publisher Id: TOBIOCJ-2-100
Article History:Received Date: 27/5/2008
Revision Received Date: 12/6/2008
Acceptance Date: 20/6/2008
Electronic publication date: 2/7/2008
Collection year: 2008
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.5/), which permits unrestrictive use, distribution, and reproduction in any medium, provided the original work is properly cited.
Over the past 10 years the serological analysis of recombinant cDNA expression libraries (SEREX) has proved to be an effective method for the identification of tumour antigens. In the present study, two prostate cancer libraries were constructed and screened using autologous sera. Fifty five genes were isolated, including 46 known genes and 9 previously uncharacterised genes. Among the known genes, a metastasis-associated gene, MTA1, previously identified by differential cDNA hybridisation, was preferentially expressed in a panel of malignant tissues compared with normal tissues, as analysed by reverse transcriptase-polymerase chain reaction (RT-PCR). MTA1 transcripts were observed to be over-expressed in normal human testes as well as various cancer tissues when compared to the panel of normal tissues. MTA1 antigen reacted with 2 of 13 allogeneic prostate cancer patient sera tested, but no sera reactivity was observed to any of the normal adult sera tested. Furthermore, a similar distribution and expression level of MTA-1 was observed in murine tissues and cancer cell lines. Based on these findings and previous reports on the literature on this gene, MTA-1 can be considered not only as a “biomarker” of aggressive disease but also as a potential therapeutic target.